Vida Press
These are expected to prevent viral infection or treat people who are already infected.
Founder and CEO of Icosagen, Tartu University Professor of Biomedical technology Mart Ustav said that they would start developing the vaccine as soon as possible and hoped to reach testing in 2016.
Ustav did not wish to forecast when the medicine could come to the market.
Delfi.ee wrote that Icosagen’s patented QMCF technology has been successfully licensed to a number of large pharmaceutical and biotechnology companies, which are used to develop and produce virus-like particles, antibodies, recombinant proteins, and other biological medicines.
“As our technology can be well applied for Ebola vaccine development, we feel an obligation to participate in the fight against Ebola,” said Ustav. “I am confident that we can contribute, with our joint work, to preventing Ebola virus infection and treatment of the disease.”
In the development, Tartu University Institute of Technology, Laboratory of Applied Virology will participate. In the clinical stage of testing vaccines and biological therapeutics, partners from France and Switzerland will join the project.
On the eve of the Independence Day of the Republic of Kazakhstan, on December 13,…
Kęstutis Budrys, the President's Senior Adviser, who has been nominated for the post of Minister…
In the heart of Bulgaria, the city of Plovdiv reveals a rich tapestry of ancient…
"We can shout very loudly, but it won't change the position of the American people,"…
From mocking messages flooding social networks to harsh criticism from political experts, the decision of…
Republic Day has been celebrated in Kazakhstan as the main national date since 2022, giving…